Table 3.
Clinical significance of clinicopathological and molecular parameters of uveal melanoma by univariate and multivariate analysis for disease-free survival (DFS) (Cox proportional-hazards model)
| Clinicopathological parameters | Disease-free survival (DFS) | |||
|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | |||
| Hazard ratio (95% confidence interval) | *p value | Hazard ratio (95% confidence interval) | *p value | |
| Largest tumor basal diameter (LBD > 15 mm) | 8.4 (1.03–12.93) | 0.047 | 1.66 (0.34–7.95) | 0.52 |
| Tumor thickness greater than 8 mm | 3.67 (1.03–12.93) | 0.043 | 1.20 (0.23–6.09) | 0.82 |
| AJCC clinical staging | 2.92 (0.94–9.08) | 0.06 | – | – |
| Scleral invasion | 3.02 (0.96–10.63) | 0.05 | – | – |
| Ciliary body invasion | 2.72 (0.80–9.28) | 0.10 | – | – |
| Epithelioid cell type | 1.73 (0.52–5.72) | 0.36 | – | – |
| Infiltrating macrophage (> 50% CD68 positivity) | 3.33 (1.00–11.09) | 0.05 | – | – |
| Microvascular density (> 50vessels/0.25 mm2) | 2.86 (0.86–9.51) | 0.08 | – | – |
| CD3+/CD4+/CD8+ (TILs) | 4.25 (1.20–15.03) | 0.025 | 2.82 (0.92–8.68) | 0.06 |
| PD-1 immunoexpression | 3.44 (1.05–11.19) | 0.040 | 3.78 (0.53–53.05) | 0.046 |
| PD-L1 immunoexpression | 12.13 (1.49–98.65) | 0.020 | 9.70 (1.04–90.48) | 0.039 |
| PD-1 mRNA expression | 2.5 (0.77–8.02) | 0.12 | – | – |
| PD-L1 mRNA expression | 2.75 (0.78–9.68) | 0.11 | – | – |
Bold signifies statistically significant value